84358-13-4 Usage
Description
N-BOC-piperidine-4-carboxylic acid is a chemical compound that serves as a pharmaceutical intermediate. It is characterized by its ability to be incorporated into various drug molecules, enhancing their properties and effectiveness.
Uses
Used in Pharmaceutical Industry:
N-BOC-piperidine-4-carboxylic acid is used as a pharmaceutical intermediate for the development of various drug molecules. It plays a crucial role in the synthesis of camptothecin ester of isonipecotic acid, which is then installed on a triazine dendrimer intermediate. This process is carried out through an iterative, scalable route, ultimately yielding cationic and PEGylated targets with activities in cell culture comparable to free drug. This application allows for the enhancement of drug properties, leading to improved therapeutic outcomes.
Check Digit Verification of cas no
The CAS Registry Mumber 84358-13-4 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 8,4,3,5 and 8 respectively; the second part has 2 digits, 1 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 84358-13:
(7*8)+(6*4)+(5*3)+(4*5)+(3*8)+(2*1)+(1*3)=144
144 % 10 = 4
So 84358-13-4 is a valid CAS Registry Number.
InChI:InChI=1/C11H19NO4/c1-11(2,3)16-10(15)12-6-4-8(5-7-12)9(13)14/h8H,4-7H2,1-3H3,(H,13,14)/p-1
84358-13-4Relevant articles and documents
Formation of quaternary carbons through cobalt-catalyzed C(sp3)-C(sp3) Negishi cross-coupling
Palao, Eduardo,López, Enol,Torres-Moya, Iván,De La Hoz, Antonio,Díaz-Ortiz, ángel,Alcázar, Jesús
supporting information, p. 8210 - 8213 (2020/08/17)
Formation of all-carbon-substituted quaternary carbons is a key challenge in organic and medicinal chemistry. We report a cobalt-catalyzed C(sp3)-C(sp3) cross-coupling that allows for the introduction of benzyl, heteroarylmethylzinc and allyl groups to halo-carbonyl substrates. The cross-coupling reaction is selective for C(sp3)-over C(sp2)-halides, in contrast to most used catalytic metals, and allows access to novel scaffolds of pharmaceutical interest. NMR mechanistic studies suggest the presence of Co(0) complexes as catalytic species. This journal is